#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Transfusion and Haematology Today / 2021 - 3

Laboratory dia­gnostics in immune-mediated thrombocytopenias

Czech version

Authors: L. Janků 1,2;  H. Lejdarová 1,2
Authors‘ workplace: Transfuzní a tkáňové oddělení, FN Brno 1;  Katedra laboratorních metod, LF MU Brno 2
Published in: Transfuze Hematol. dnes,27, 2021, No. 3, p. 232-239.
Category: Review/Educational Papers
doi: https://doi.org/10.48095/cctahd2021232

Overview

Immune-mediated thrombocytopenias are caused by alloantibodies or autoantibodies directed against platelet surface antigens. This group of immune disorders is divided into five types of thrombocytopenias in which platelet antibody testing is possible: immune thrombocytopenia, drug-induced immune thrombocytopenia, foetal and neonatal alloimmune thrombocytopenia, post-transfusion purpura, multi-platelet transfusion refractoriness. Laboratory testing involves detection and identification of patient serum antibodies using indirect tests or antibodies attached to patient platelets using direct tests. The analysis of blood samples for platelet antibody detection is complicated due to insufficient sensitivity of some laboratory tests. Identification of platelet-specific HPA antibodies provides important information, which facilitates the clinical dia­gnosis of immune-mediated disorder.

Keywords:

immune-mediated thrombocytopenia – HPA – HLA

Sources
  1. Rinder HM, Tomer A. Platelet production, kinetics, and hemostasis. In: Simon TL, Snyder EL, Solheim BG et al. Rossi’s principles of transfusion medicine. 4th ed., Blackwell Publishing 2009; 149–167.
  2. Varghese LN, Defour JP, Pecquet Ch, Constantinescu SN. The thrombopoietin receptor: structural basis of traffic and activation by ligand, mutations, agonists, and mutated calreticulin. Front Endocrinol. 2017; 8: 59. publikováno elektronicky 31. března 2017. DOI: 10.3389/fendo.2017.00059.
  3. Gauer RL, Braun MM. Thrombocytopenia. Am Fam Physician. 2012; 85 (6): 612–622.
  4. Lochowitz AJ, Curtis BR. Clinical applications of platelet antibody and antigen testing. Lab Med. 2011; 42 (11): 687–692.
  5. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010; 115 (2): 168–186.
  6. Curtis BR, McFarland JG. Platelet immunology and alloimmunization. In: Simon TL, Snyder EL, Solheim BG et al. Rossi’s principles of transfusion medicine. 4th ed., Blackwell Publishing 2009; 168–186.
  7. Ouabdelmoumene Z, El Housse H, Zarati F, et al. Frequencies of human platelet antigens (HPA-1, -2, -3, -4, and -5) among the Moroccan blood donors. Int J Blood Transfus Immunohematol. 2018; 8: 100038Z02ZO2018.
  8. Curtis BR, McFarland JG. Human platelet antigens – 2013. Vox Sang. 2014; 106: 93–102.
  9. Metcalfe P. Platelet antigens and antibody detection. Vox Sang 2004; 87 (Suppl.1): 82–86.
  10. Heikal NM, Smock KJ. Laboratory testing for platelet antibodies. Am J Hematol. 2013; 88: 818–821.
  11. Porcelijn L, Huiskes E, de Haas M. Progress and development of platelet antibody detection. Transfus Apher Sci. 2020; 59 (1): 102 705.
  12. Porcelijn L, Huiskes E, Comijs-van Osselen I, et al. A new bead-based human platelet antigen antibodies detection assay versus the monoclonal antibody immobilization of platelet antigens assay. Transfusion. 2014; 54: 14861–1492.
  13. Maślanka K, Michur H, Guz K, et al. The relevance of HPA-15 antigen expression for anti-HPA-15 antibody detection. Int Jnl Lab Hem. 2012; 34: 65–69.
  14. Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood 2009; 113: 6511–6521.
  15. Matzdorff A, Meyer O, Ostermann H, et al. Immune thrombocytopenia – current dia­gnostics and therapy: recommendations of a joint working group of DGHO, ÖGHO, SGH, GPOH, and DGTI. Oncol Res Treat. 2018; 41 (suppl 5): 1–30.
  16. Swinkels M, Rijkers M, Voorberg J, Vidarsson G, Leebeek FWG, Jansen AJG. Emerging concepts in immune thrombocytopenia. Front Immunol; publikováno elektronicky 30. dubna 2018. DOI: 10.3389/fimmu.2018.00880.
  17. Nishioka T, Yamane T, Takubo T, Ohta K, Park K, Hino M. Detection of various platelet-associated immunoglobulins by flow cytometry in idiopathic thrombocytopenic purpura. Cytometry B Clin Cytom. 2005; 68 (1): 37–42.
  18. Jernas M, Hou Y, Stromberg Celid F, et al. Differences in gene expresion and cytokine levels between newly dia­gnosed and chronic pediatric ITP. Blood. 2013; 122 (10): 1789–1792.
  19. Rose NR. Negative selection, epitope mimicry and autoimmunity. Curr Opin Immunol. 2017; 49: 51–55.
  20. Cooper N. State of the art – how I manage immune thrombocytopenia. Br J Haematol. 2017; 177: 39–54.
  21. Hamidpour M, Khalili G, Tajic N, Shamsian BS, Hamidpour R. Comparative of three methods (ELIZA, MAIPA and flow cytometry) to determine anti-platelet antibody in children with ITP. Am J Blood Res. 2014; 4 (2): 86–92.
  22. Teraz-Orosz A, Cooper N, Crawley JTB, Salles-Crawley II. Detection of anti-platelet antibodies in immune thrombocytopenia by flow cytometry. Br J Haematol. 2019; 184 (5): 844–847.
  23. Aster RH, Curtis BR, McFarland JG, Bougie DW. Drug-induced immune thrombocytopenia: pathogenesis, dia­gnosis and management. J Thromb Haemost. 2009; 7 (6): 911–918.
  24. George JN, Aster RH. Drug-induced thrombocytopenia: pathogenesis, evalution, and management. Hematology Am Soc Hematol Educ Program. 2009; 153–158.
  25. Arnold DM, Nazi I, Warkentin TE, et al. Approach to the dia­gnosis and management of drug-induced immune thrombocytopenia. Transfus Med Rev. 2013; 27 (3): 137–145.
  26. Royer DJ, George JN, Terrell DR. Thrombocytopenia as an adverse effect of complementary and alternative medicines, herbal remedies, nutritional supplements, foods, and beverages. Eu J Haematol. 2010; 84: 421–429.
  27. Arnold DM, Kukaswadia S, Nazi I, et al. A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia. J Thromb Haemost. 2013; 11 (1): 169–176.
  28. McFarland JG. Detection and identification of platelet antibodies in clinical disorders. Transfus Apher Sci. 2003; 28: 297–305.
  29. Regan F, Lees CC, Jones B, Nicolaides KH, Wimalasundera RC, Mijovic A, on behalf of the royal college of obstetricians and gynaecologists. Prenatal management of pregnancies at risk of fetal neonatal alloimmune thrombocytopenia (FNAIT). Scientific impact paper No. 61. BJOG. 2019; 126: e173–e185.
  30. Mella MT, Eddleman K. Neonatal alloimmune thrombocytopenia. Int J Clin Transf Med. 2015 3: 29–40.
  31. Curtis BR. Recent progress in understanding the pathogenesis of fetal and neonatal alloimmune thrombocytopenia. Br J Haematol. 2015; 171: 671–682.
  32. Wienzek-Lischka S, König IR, Papenkort EM, et al. HLA-DRB3*01: 01 is a predictor of immunization against human platelet antigen-1a but not of the severity of fetal and neonatal alloimmune thrombocytopenia. Transfusion. 2017; 57: 533–540.
  33. Loewenthal R, Rosenberg N, Kalt R, et al. Compound heterozygosity of HLA-DRB3*01: 01 and HLA-DRB4*01: 01 as a potential predictor of fetal neonatal alloimmune thrombocytopenia. Transfusion. 2013; 53: 344–352.
  34. Delbos F, Bertrand G, Croisille L, Ansart-Pirenne H, Bierling P, Kaplan C. Fetal and neonatal alloimmune thrombocytopenia: predictive factors of intracranial hemorrhage. Transfusion. 2016; 56: 59–66.
  35. Masson E, Vidal C, Deschamps M, et al. Incidence and risk factors of anti-HLA immunization after pregnancy. Hum Immunol. 2013; 74 (8): 946–951.
  36. Saito S, Ota M, Komatsu Y, et al. Serologic analysis of three cases of neonatal alloimmune thrombocytopenia associated with HLA antibodies. Transfusion. 2003; 43 (7): 908–917.
  37. Starcevic M, Tomicic M, Malenica M, Zah-Matakovic V. Neonatal alloimmune thrombocytopenia caused by anti-HLA-A24 alloantibodies. Acta Paediatr. 2010; 99: 630–632.
  38. Dahl J, Refsum E, Ahlen MT, et al. Unraveling the role of maternal anti-HLA class I antibodies in fetal and neonatal thrombocytopenia – antibody specificity analysis using epitope data. J Reprod Immunol. 2017; 122: 1–9.
  39. Schallmoser K, Kutschera J, Macher S, et al. Delayed detectability of anti-HPA-3a by the MAIPA assay in a severe neonatal alloimmune thrombocytopenia, but successful transfusion of incompatible donor platelets: a case report. Vox Sang. 2006; 91: 181–183.
  40. Cooper N, Bein G, Heidinger K, Santoso S, Sachs UJ. A bead-based assay in the work-up of suspected platelet alloimmunization. Transfusion. 2016; 56: 115–118.
  41. Bonstein L, Haddad N. Taking a wider view on fetal/neonatal alloimmune thrombocytopenia. Thromb Res. 2017; 151 (Suppl 1): 100–102.
  42. Petermann R, Bakchoul T, Curtis BR, Mullier F, Miyata S, Arnold DM, for the Subcommittee on Platelet Immunology. Investigations for fetal and neonatal alloimmune thrombocytopenia: communication from the SSC of the ISTH. J Thromb Haemost. 2018; 16: 2526–2529.
  43. Albalawi M, Zolaly M, Alkhayat N, Al Sharif O, Elyamany G. Current understanding of post transfusion purpura: a systematic review. J Am Sci. 2015; 11 (10): 146–151.
  44. Taaning E, Tonnesen F. Pan-reactive platelet antibodies in post-transfusion purpura. Vox Sang. 1999; 76: 120–123.
  45. Hawkins J, Aster RH, Curtis BR. Post-transfusion purpura: current perspectives. J Blood Med. 2019; 10: 405–415.
  46. Rafei H, Yunus R, Nassereddine S. Post- transfusion purpura: a case report of an underdia­gnosed phenomenon. Cureus. 2017; 9 (5): e1207. Publikováno elektronicky 1. května 2017. DOI: 10.7759/cureus.1207.
  47. Farhadfar N, Desai A, Sivapiragasam A, Harris J, Desai A, Hindenburg A. Dia­gnosis and management of post transfusion purpura: a case report. J Clin Case Rep. 2015; 5: 6. Publikováno elektronicky 9. června 2015. DOI: 10.4172/2165-7920.1000550.
  48. Shtalrid M, Shvidel L, Vorst E, Weinmann EE, Berrebi A, Sigler E. Post-transfusion purpura: a challenging dia­gnosis. Isr Med Assoc J. 2006; 8: 672–674.
  49. Hod E, Schwartz J. Platelet transfusion refractoriness. Br J Haematol. 2008; 142: 348–360.
  50. Stanworth SJ, Navarrete C, Estcourt L, Marsh J. Platelet refractoriness – practical approaches and ongoing dilemmas in patient management. Br J Haematol. 2015; 171: 297–305.
  51. Juskewitch JE, Norgan AP, De Goey SR, et al. How do I manage the platelet transfusion-refractory patient? Transfusion. 2017; 57: 2828–2835.
  52. Rioux-Massé B, Cohn C, Lindgren B, Pulkrabek S, McCullough J. Utilization of cross-matched or HLA-matched platelets for patients refractory to platelet transfusion. Transfusion. 2014; 54: 3080–3087.
Labels
Haematology Internal medicine Clinical oncology
New insights into the pathophysiology of Ph-negative myeloproliferative neoplasms
Changes in the immune system in untreated patients with chronic lymphocytic leukaemia – part 2: innate immune system
POEMS syndrome – a rare disease associated with monoclonal gammopathy and polyneuropathy: dia­gnosis and treatment
Ph negative myeloproliferative neoplasms in Czech haematological centres – MIND analysis
Cryopreserved buffy-coat-derived platelets in platelet additive solution
Multiple lymph node plasmacytosis with monoclonal gammopathy – plasma cell neoplasm or indolent B-lymphoma?
Primář MUDr. Jiří Horák, 11. 6. 1936 – 21. 6. 2021
Article was published in

Transfusion and Haematology Today

Issue 3
2021 Issue 3
Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#